IntoCell, a corporations specializing in an antibody-drug conjugate (ADC) platform, has moved to reorganize its structure around business development (BD) experts.
According to IntoCell on the 21st, newly joined members include Senior Executive Director Gu Hyun-young, who recently led business development at ToolGen, and Jang Jin-hyeok, former Director of business development at InnoCure Therapeutics.
New IntoCell Business Development Center Head Gu Hyun-young earned a Ph.D. in science from the University of Illinois and worked as a researcher at Northwestern University and the University of Chicago. Gu then served as the Deputy Minister of business development at AtoGen, a biotech venture for new drug development and a subsidiary of the cosmetics manufacturing and sales corporations TONYMOLY. At ToolGen, Gu, as head of business development, oversaw technology transfer of major pipelines and patents.
Head of Team Jang Jin-hyeok majored in life sciences at the University of Toronto in Canada and graduated from the Department of Pharmaceutical Industry at Sungkyunkwan University Graduate School. After working at the German multinational pharmaceutical company Merck, Jang handled various business development roles at Whan In Pharm, Corestemchemon, and InnoCure Therapeutics.
IntoCell has been working to strengthen its BD workforce to expand its global business. Having completed the reorganization of the BD unit, the company plans to expand technology transfer and new partnerships with global corporations.
An IntoCell official said, "Clinical data is scheduled to be secured in the near future, and as collaboration with global big pharma is expected to expand afterward, this reinforcement of the BD organization will further accelerate IntoCell's growth potential and the drive for technology commercialization."